Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Divestments (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Divestments for 17 consecutive years, with $279.0 million as the latest value for Q4 2025.

  • Quarterly Divestments fell 16.22% to $279.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 2.55% year-over-year, with the annual reading at $1.1 billion for FY2025, 2.55% down from the prior year.
  • Divestments for Q4 2025 was $279.0 million at Bristol Myers Squibb, roughly flat from $279.0 million in the prior quarter.
  • The five-year high for Divestments was $490.0 million in Q4 2022, with the low at $178.0 million in Q4 2021.
  • Average Divestments over 5 years is $256.6 million, with a median of $242.0 million recorded in 2023.
  • The sharpest move saw Divestments skyrocketed 175.28% in 2022, then crashed 50.82% in 2023.
  • Over 5 years, Divestments stood at $178.0 million in 2021, then skyrocketed by 175.28% to $490.0 million in 2022, then plummeted by 50.82% to $241.0 million in 2023, then soared by 38.17% to $333.0 million in 2024, then fell by 16.22% to $279.0 million in 2025.
  • According to Business Quant data, Divestments over the past three periods came in at $279.0 million, $279.0 million, and $270.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.